title: Implications of Parkinson's disease pathophysiology for the development of cell replacement strategies and drug discovery in neurodegenerative diseases.
abstract: Parkinson's disease (PD) is a progressive neurodegenerative disorder traditionally characterized by the loss of dopaminergic neurons in the substantia nigra (SN) at the midbrain. The potential use of adult or embryonic stem cells, induced pluriputent stem (iPS) cells and endogenous neurogenesis in cell replacement strategies has lead to numerous studies and clinical trials in this direction. It is now possible to differentiate stem cells into dopaminergic neurons in vitro and clinical trials have shown an improvement in PD-related symptoms after intra-striatal embryonic transplants and acceptable cell survival rates on the mid term. However, clinical improvement is transitory and associated with a strong placebo effect. Interestingly, recent pathological studies in PD patients who received embryonic stem cells show that in PD patients, grafted neurons show PD-related pathology. In this manuscript we review the latest findings regarding PD pathophysiology and give an outlook on the implications of these findings in how cell replacement strategies for PD treatment should be tested. These include changes in the type of animal models used, the preparation/conditioning of the cells before intracerebral injection, specially regarding backbone chronic diseases in iPS cells and determining the optimal proliferation, survival, differentiation and migration capacity of the grafted cells.
authors.affiliation: Institute for Anatomy, Faculty of Medicine Carl Gustav Carus, TU-Dresden, Fetscherstrasse 74, Dresden, Germany. panmonto@mpi-cbg.de
authors.forename: Francisco
authors.initials: F
authors.lastname: Pan-Montojo
authors.forename: Richard H W
authors.initials: RH
authors.lastname: Funk
mesh_terms: D000818:Animals; D018726:Anti-Dyskinesia Agents / Q000494:pharmacology / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D018450:Disease Progression; D059290:Dopaminergic Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology / Q000637:transplantation*; D055808:Drug Discovery / Q000639:trends*; D053595:Embryonic Stem Cells / Q000166:cytology / Q000378:metabolism / Q000473:pathology / Q000637:transplantation; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology / Q000378:metabolism / Q000473:pathology / Q000637:transplantation; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D055495:Neurogenesis / Q000187:drug effects*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology / Q000637:transplantation; D010300:Parkinson Disease / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*
chemical_list: D018726:Anti-Dyskinesia Agents; D000978:Antiparkinson Agents